OV329 bets that Phase 1 GABAergic signal translates to seizure reduction in Phase 2 treatment-resistant focal epilepsy patients

Bull

A clean Phase 2a initiation with robust enrollment and parallel open-label photo paroxysmal response data showing measurable cortical inhibition would validate the mechanistic bridge from Phase 1. Dose-dependent reduction in seizure frequency across the two dose levels, with a safety and tolerability profile consistent with Phase 1 findings, would confirm the GABAergic hypothesis and support accelerated development across OV329's expanding indication set including TSC and infantile spasms.

Bear

The most significant failure mode is a lack of efficacy signal — if the GABAergic pharmacodynamic effect seen in healthy volunteers does not translate to seizure frequency reduction in treatment-resistant focal epilepsy patients, the core thesis collapses. Dose-limiting tolerability issues at therapeutically relevant exposures, or poor trial execution leading to underpowered or confounded data, would similarly undermine confidence in advancing OV329 to later-stage development.